TransPharma Medical TransPharma Medical    |    Home    |    Contact Us    |   
 About
 Technology
 ViaDerm System
 Drug Product Portfolio
 Potential Product
 Applications
 Strategic Partnerships
 Publications
 News & Events
Management Board of Directors Clinical Advisory Board
About Us  | Company Profile
Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transdermal drug delivery technology. Our current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1.

TransPharma’s drug-product development activities utilize our well-proven RF-MicroChannel Technology. Our RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, our main area of focus. TransPharma’s implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug.

TransPharma’s goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. We believe that combining partnered and proprietary product development ensures capitalizing of both the promise of our technology and our growing capabilities.

Back to Top  

Terms of Use

  © TransPharma Medical™ Ltd. All Rights Reserved.
updated May 2008